Table 3.

Clinic-pathological features of the “IPTW” cohort.

Characteristics		Denosumab	Zoledronic Acid	p value	SMD
n		617	759
Premenopausal State	No	476 (77.1 %)	606 (79.8 %)	0.252	0.066
	Yes	141 (22.9 %)	153 (20.2 %)
Age (mean ± SD)		61.4 ± 12.4	61.5 ± 11.6	0.905	0.007
PS	0	529 (85.7 %)	665 (87.6 %)	0.346	0.055
	1	88 (14.3 %)	94 (12.4 %)
Histology	Ductal	432 (70.0 %)	520 (68.5 %)	0.799	0.036
	Lobular	137 (22.2 %)	180 (23.7 %)
	Other	48 (7.8 %)	59 (7.8 %)
Ki67 (mean ± SD)		22.7 ± 14.4	21.8 ± 14.4	0.271	0.062
Grading	G1-G2	292 (64.6 %)	406 (65.2 %)	0.899	0.012
	G3	160 (35.4 %)	217 (34.8 %)
Estrogen Receptor (mean ± SD)		86.1 ± 15.7	86.2 ± 15.4	0.899	0.007
Progesterone Receptor (mean ± SD)		45.8 ± 37.2	46.3 ± 36.1	0.817	0.014
Metastatic at Diagnosis	No	351 (56.9 %)	399 (52.6 %)	0.122	0.087
	Yes	266 (43.1 %)	360 (47.4 %)
Adjuvant Chemotherapy	No	381 (61.8 %)	480 (63.2 %)	0.608	0.031
	Yes	236 (38.2 %)	279 (36.8 %)
Adjuvant Endocrine Therapy	No	245 (39.7 %)	298 (39.3 %)	0.91	0.009
	Yes	372 (60.3 %)	461 (60.7 %)
Months of Adjuvant Endocrine Therapy (mean ± SD)		48.2 ± 29.1	44.4 ± 31.2	0.075	0.125
BoneOnly	No	285 (46.2 %)	364 (48.0 %)	0.549	0.035
	Yes	332 (53.8 %)	395 (52.0 %)
CDK4/6 Inhibitor	Abemaciclib	85 (13.8 %)	98 (12.9 %)	0.837	0.032
	Palbociclib	352 (57.0 %)	444 (58.5 %)
	Ribociclib	180 (29.2 %)	217 (28.6 %)
Line of Treatment	First	485 (78.6 %)	609 (80.2 %)	0.498	0.04
	Second	132 (21.4 %)	150 (19.8 %)
Setting	Endocrine Resistant	270 (43.8 %)	328 (43.2 %)	0.882	0.011
	Endocrine Sensitive	347 (56.2 %)	431 (56.8 %)
Endocrine Therapy	Aromatase Inhibitor	389 (63.0 %)	462 (60.9 %)	0.441	0.045
	Fulvestrant	228 (37.0 %)	297 (39.1 %)